Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0001511 (
Adhesion
)
5,955
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously showed that thrombospondin 1 (TSP-1) upregulates the plasminogen/plasmin system and promotes breast tumor cell invasion. Preliminary data from our laboratory using neutralizing antibodies suggested that the upregulation in breast tumor cell invasion seen in response to TSP-1 involved the
urokinase plasminogen activator receptor
(
uPAR
). To confirm these findings in MDA-MB-231 breast cancer cells, we developed three other strategies to study the role of
uPAR
in tumor cell adhesion and TSP-1-mediated tumor cell invasion: (a) enzymatic cleavage of
uPAR
with glycosylphosphatidylinositol-specific phospholipase C; (b) inhibition at the mRNA level with a
uPAR
antisense construct (cells named LKAS-MDA); (c) inhibition of plasminogen binding with the lysine analogue epsilon-aminocaproic acid.
Adhesion
to laminin and type I and type IV collagen with and without the addition of epsilon-aminocaproic acid was studied. Tumor cell invasion was studied in a modified Boyden chamber collagen invasion assay. Antisense
uPAR
inhibition decreased
uPAR
expression by 48-66% and cell-associated urokinase plasminogen activator (uPA) by 30-68%. Additionally, antisense
uPAR
inhibition induced a 68-70% reduction in uPA and plasmin activities. Antisense
uPAR
transfection increased tumor cell adhesion by 46-53%. A similar effect was observed in epsilon-aminocaproic acid-treated MDA-MB-231 cells. TSP-1-mediated tumor cell invasion was almost completely inhibited by either antisense
uPAR
inhibition or treatment with phospholipase C or epsilon-aminocaproic acid. We conclude that
uPAR
plays a crucial role in the regulation of tumor cell adhesion and TSP-1-mediated tumor cell invasion.
...
PMID:Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion. 1009 Aug 48
Mechanisms that regulate the transition of metastases from clinically undetectable and dormant to progressively growing are the least understood aspects of cancer biology. Here, we show that a large ( approximately 70%) reduction in the
urokinase plasminogen activator receptor
(
uPAR
) level in human carcinoma HEp3 cells, while not affecting their in vitro growth, induced a protracted state of tumor dormancy in vivo, with G(0)/G(1) arrest. We have now identified the mechanism responsible for the induction of dormancy. We found that uPA/
uPAR
proteins were physically associated with alpha5beta1, and that in cells with low
uPAR
the frequency of this association was significantly reduced, leading to a reduced avidity of alpha5beta1 and a lower adhesion of cells to the fibronectin (FN).
Adhesion
to FN resulted in a robust and persistent ERK1/2 activation and serum-independent growth stimulation of only
uPAR
-rich cells. Compared with
uPAR
-rich tumorigenic cells, the basal level of active extracellular regulated kinase (ERK) was four to sixfold reduced in
uPAR
-poor dormant cells and its stimulation by single chain uPA (scuPA) was weak and showed slow kinetics. The high basal level of active ERK in
uPAR
-rich cells could be strongly and rapidly stimulated by scuPA. Disruption of
uPAR
-alpha5beta1 complexes in
uPAR
-rich cells with antibodies or a peptide that disrupts
uPAR
-beta1 interactions, reduced the FN-dependent ERK1/2 activation. These results indicate that dormancy of low
uPAR
cells may be the consequence of insufficient uPA/
uPAR
/alpha5beta1 complexes, which cannot induce ERK1/2 activity above a threshold needed to sustain tumor growth in vivo. In support of this conclusion we found that treatment of
uPAR
-rich cells, which maintain high ERK activity in vivo, with reagents interfering with the
uPAR
/beta1 signal to ERK activation, mimic the in vivo dormancy induced by downregulation of
uPAR
.
...
PMID:Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. 1050 58
Engagement of adhesion molecules on monocytes and other myeloid leukocytes, which are effector cells of the innate immune system, not only tethers the leukocytes in place but also transmits outside-in signals that induce functional changes and alter gene expression. We found that a subset of mRNAs that are induced or amplified by adhesion of human monocytes to P-selectin via its surface ligand, P-selectin glycoprotein 1, have characteristics that suggest specialized translational control. One of these codes for
urokinase plasminogen activator receptor
(
UPAR
), a critical surface protease receptor and regulator of cell adhesion and migration. Although
UPAR
transcripts are induced by adhesion, rapid synthesis of the protein uses constitutive mRNA without a requirement for new transcription and is regulated by mammalian target of rapamycin, demonstrating new biologic roles for the signal-dependent translation pathway controlled by this intracellular kinase. The synthesis of
UPAR
in monocytic cells is also regulated by eukaryotic translation initiation factor 4E, a second key translational checkpoint, and phosphorylation of eukaryotic translation initiation factor 4E is induced by adhesion of monocytes to P-selectin. Translationally controlled display of
UPAR
by monocytes confers recognition of the matrix protein, vitronectin.
Adhesion
-dependent signaling from the plasma membrane to translational checkpoints represents a previously unrecognized mechanism for regulating surface phenotype that may be particularly important for myeloid leukocytes and other cells that are specialized for rapid inflammatory and vascular responses.
...
PMID:Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes. 1151 14
Epithelial ovarian cancer cells metastasize by implanting onto the peritoneal mesothelial surface of the abdominal cavity. Adhesive molecules that lead to this implantation remain unclear. The aim of our study was to focus on the role of vitronectin (Vn) and its receptors, alpha(v) integrins and
urokinase plasminogen activator receptor
(
uPAR
), in the interactions of ovarian adenocarcinoma cells (IGROV1 and SKOV3 cell lines) with mesothelial cells (MeT-5A cell line and primary cultures). For all cell lines, immunofluorescence staining disclosed the presence of Vn over the whole cell surface and in thin continuous deposits underlining the cell periphery. Recruitment of Vn receptors to cell-cell contact sites was also revealed. We developed two distinct methods for the evaluation of in vitro cell-cell adhesion using cocultures of the tumor and mesothelial cells. Both adhesion assays revealed a strong ability of ovarian cancer cells to adhere preferentially to mesothelial intercellular junctions.
Adhesion
of ovarian carcinoma cells to mesothelial cells was significantly inhibited using anti-Vn-, -alpha(v)-integrin- and -
uPAR
-blocking antibodies or cyclic peptide cRGDfV. These results evidence the ability of ovarian carcinoma cells to bind to peritoneal mesothelium in vitro and strongly suggest that Vn and its receptors contribute to this crucial event.
...
PMID:Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. 1878 Oct 95